Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Phase 2 trials investigated once-weekly subcutaneous doses of 1 mg to 12 mg with gradual escalation, but no regulatory authority has yet approved the medicine
A meta-analysis conducted by Wang et al
CNS Neurosci Ther 30(8):e14895
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Some researchers believe the effects of losing weight through GLP-1 agonists may help with the regulation of these sex hormones in those who are clinically obese
US$ 28.01
US$ 20.75
US$ 26.88
US$ 27.30
US$ 24.51
